Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1 [Retraction]


At the request of the author, the Editor and Publisher of OncoTargets and Therapy wish to retract the published paper.

Following a review of their paper the authors have determined that due to a lack of data they can no longer confirm this study showed an anti-cancer role of exosome miR-638 in hepatocellular carcinoma (HCC) by inhibiting angiogenesis. The authors also confirmed they could no longer locate the original data for this study. In the interests of scientific integrity, the authors have agreed it best to retract the published article.

The Editor has determined the findings of the paper are no longer valid and has agreed with the authors request to retract the article.

The author wished to apologise for this error.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

---

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal